The precision cancer business of PHC Holdings anticipates an increase in cancer cases and is expanding its digital pathology and immunohistochemistry instrument lineup.

Preclinical models of Parkinson's disease (PD) have been developed using intracerebroventricular (i.c.v.) injection of 6-hydroxydopamine (6-OHDA) to induce neurodegeneration and motor dysfunction.

A Chinese research team has developed an AI tool that predicts liver cancer recurrence risk with 82.2 percent accuracy, ...

Breast cancer is the most prevalent in Nigeria with over 32,000 cases yearly. Half of the women diagnosed with breast cancer ...

Zentalis estimates that about half of PROC patients overexpress Cyclin E1 based on its proprietary immunohistochemistry cutoff. As of the January 13, 2025 data cutoff, the safety and tolerability ...

The instrument is used for advanced immunohistochemistry, in situ hybridization, and fluorescence in situ hybridization applications.

A multinational healthcare company, Roche and a provider of digital integrated healthcare services, Oncopadi Technologies ...

Swiss pharma giant, Roche, in collaboration with Oncopadi Technologies, has launched a Breast Cancer Access Navigation and Testing Programme ...

The programme aims to enhance early detection and ensure timely, accurate breast cancer diagnosis by offering free immunohistochemistry tests, multidisciplinary care, and navigation services to 5,000 ...

Canadian researchers have developed an effective new technique for identifying aggressive medulloblastoma—the most common ...

A research team led by Prof. Sun Cheng from the University of Science and Technology of China (USTC), in collaboration with ...